Compare KSS & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | FTRE |
|---|---|---|
| Founded | 1962 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 1995 | 2023 |
| Metric | KSS | FTRE |
|---|---|---|
| Price | $22.04 | $21.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $18.88 | ★ $21.04 |
| AVG Volume (30 Days) | ★ 3.5M | 1.5M |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 142.86 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.04 | $3.19 |
| P/E Ratio | $17.92 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $11.38 | $8.55 |
| 52 Week High | $25.22 | $23.51 |
| Indicator | KSS | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 75.31 | 66.73 |
| Support Level | $16.19 | $16.92 |
| Resistance Level | N/A | $23.51 |
| Average True Range (ATR) | 0.89 | 1.05 |
| MACD | 0.33 | 0.09 |
| Stochastic Oscillator | 99.32 | 62.89 |
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.